Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TBX2
REST API REST API
Homo sapiens
TBX2 is differentially expressed in 259 experiments: 137 organism parts: lung, placenta, ... (135 more);, 163 disease states: normal, glioblastoma, ... (161 more);, 90 cell types 398 cell lines 36 compound treatments and 67 other conditions.
Orthologs tbx2b (Danio rerio)   tbx2a (Danio rerio)   Tbx2 (Mus musculus)   TBX2 (Gallus gallus)   TBX2 (Bos taurus)   F1M0C0_RAT (Rattus norvegicus)   Q4JF70_CIOIN (Ciona intestinalis)   bi (Drosophila melanogaster)   tbx2 (Xenopus laevis)   TBX2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, regulation of transcription, DNA-dependent, muscle cell fate determination, transcription, DNA-dependent, positive regulation of cell proliferation, heart morphogenesis, cardiac muscle tissue development, sequence-specific DNA binding, multicellular organismal development, nucleus, transcription factor complex, negative regulation of transcription from RNA polymerase II promoter, cell aging, developmental growth involved in morphogenesis, mammary placode formation, palate development, sequence-specific DNA binding transcription factor activity
InterPro Term TF_T-box, TF_Brachyury, TBX
UniProt Accession Q13207, F8WCM9
Search EB-eye ENSG00000121068
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-2549, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MDA468
2
E-MTAB-62, E-MEXP-440
BT-474
2
E-GEOD-5823, E-GEOD-3529
392 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (37 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
spermatid
1
E-TABM-130
effector memory T cell
1
E-GEOD-3982
Kaposi's sarcoma cell
1
E-MEXP-66
leydig cell
1
E-MTAB-25
activated B-cell
1
E-MEXP-2360
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (57 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-6014
lung adenocarcinoma
3
E-MTAB-37, E-GEOD-2514, E-MEXP-231
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-3868
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
colon carcinoma
2
E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
157 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-TABM-868, E-GEOD-6462, ... (22 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5824, E-GEOD-412, E-TABM-868, E-GEOD-4600, E-MEXP-1389, ... (6 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
TNF
1
E-GEOD-15205
1mM GDC-0941
1
1
E-GEOD-20719
vehicle
1
E-GEOD-4025
Cxcl12
1
1
E-GEOD-7307
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-MEXP-1103, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-4922

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-4600

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922, E-TABM-147

Vehicle
studied in E-GEOD-5258

Processing time: 0.373 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM